Heart attack survivors: new drug may cut risk of another cardiac event
NCT ID NCT06740552
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This completed study looked at whether evolocumab, a cholesterol-lowering injection, can reduce major heart problems in people who had a heart attack and have several blocked arteries. Researchers analyzed data from 1862 patients to see if the drug lowers the risk of cardiac death, another heart attack, or heart failure hospitalization. The study used existing medical records rather than a traditional trial, so results are suggestive but not definitive.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
evolocumab (a cholesterol-lowering injection given every two weeks)
What this could lead to
If it works, this could show that evolocumab reduces the chance of another heart attack or heart failure in people with multiple blocked arteries after a first heart attack.
What could go wrong
This is a completed observational analysis, not a controlled experiment, so results may be less reliable. The benefit may be small or not apply to everyone.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYOCARDIAL INFARCTION (AMI) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Zhongshan Hospital, Fudan University
Shanghai, Shanghai Municipality, 200000, China